Trials / Completed
CompletedNCT00464568
A 5-way Treatment Period Trial of Single Doses of Intranasal GSK256066 in Patients With Rhinitis
A Randomised, Open, Placebo-controlled 5-way Crossover Trial of Single Doses of Intranasal GSK256066 in Subjects With Seasonal Allergic Rhinitis (SAR).
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 32 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Not accepted
Summary
This current study is planned as a dedicated pharmacodynamic (effect of drug on the body) study to investigate the dose response in rhinitic subjects at doses where GSK256066 has been proven to work (200mcg) or expected to (50mcg) work. This study also aims to investigate the lower end of the predicted therapeutic range.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GSK256066 |
Timeline
- Start date
- 2007-03-28
- Primary completion
- 2007-05-16
- Completion
- 2007-05-16
- First posted
- 2007-04-23
- Last updated
- 2018-08-20
- Results posted
- 2017-08-21
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT00464568. Inclusion in this directory is not an endorsement.